Acrivon Therapeutics (ACRV) Retained Earnings (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Retained Earnings of $4000.0 for Q1 2026, up 100.0% year-over-year from $2000.0 in Q1 2025, and down 96.4% quarter-over-quarter from $111000.0 in Q4 2025.
Acrivon Therapeutics (ACRV) Retained Earnings (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Retained Earnings for 6 consecutive years, with $4000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 100.0% year-over-year to $4000.0; the TTM figure through Mar 2026 stood at $4000.0 (up 100.0% YoY), while the FY2025 annual figure was $111000.0, down 99.97% from the prior year.
- Retained Earnings fell to $4000.0 in Q1 2026 per ACRV's latest filing, from $111000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $384.4 million in Q3 2025 and bottomed at -$237.7 million in Q2 2025.
- Historically, Retained Earnings has averaged $20.0 million across 5 years, with a median of -$302000.0 in 2023.
- Annual changes were most pronounced in 2023 — Retained Earnings slumped 151.38% — and 2024, when it soared 122690.73%.
- Acrivon Therapeutics' Retained Earnings stood at $226.6 million in 2022, then plunged by 151.38% to -$116.4 million in 2023, then surged by 420.64% to $373.3 million in 2024, then sank by 99.97% to $111000.0 in 2025, then sank by 96.4% to $4000.0 in 2026.
- Business Quant data shows ACRV's Retained Earnings at $4000.0 in Q1 2026, $111000.0 in Q4 2025, and $384.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 4.38 Bn |
| 10 | Acrivon Therapeutics | 91.64 Mn | 91.64 Mn | - | 398.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 398.54 Mn |
| Mar 31, 2026 | 4,000.00 |
| Dec 31, 2025 | 111,000.00 |
| Sep 30, 2025 | 384.36 Mn |
| Jun 30, 2025 | -237.66 Mn |
| Mar 31, 2025 | -216.70 Mn |
| Dec 31, 2024 | 373.28 Mn |
| Sep 30, 2024 | 370.22 Mn |
| Jun 30, 2024 | -151.70 Mn |
| Mar 31, 2024 | -132.90 Mn |
| Dec 31, 2023 | -116.42 Mn |
| Sep 30, 2023 | -302,000.00 |
| Jun 30, 2023 | -82.70 Mn |
| Mar 31, 2023 | -116.40 Mn |
| Dec 31, 2022 | 226.58 Mn |
| Sep 30, 2022 | -133,000.00 |
| Dec 31, 2021 | 1.05 Mn |